Denosumab Wins Drug Award

Publication
Article
Oncology Live®December 2010
Volume 11
Issue 12

At the 6th Annual Scrip Awards, featuring more than 500 representatives from the pharmaceutical industry, Amgen received the Best New Drug award for denosumab, the first approved inhibitor of RANK ligand.

At the 6th Annual Scrip Awards, featuring more than 500 representatives from the pharmaceutical industry, Amgen received the Best New Drug award for denosumab, the first approved inhibitor of RANK ligand. The Scrip honor, announced at a London gala on November 4, recognized the use of denosumab under the brand name Prolia, an approved treatment for osteoporosis in postmenopausal women with a high risk of fracture. Later in November, the FDA approved denosumab (Xgeva) for the prevention of skeletal-related events in patients with bone metastases from solid tumors. The European Union has already approved denosumab for certain men with prostate cancer who are suffering from bone loss that is related to hormone ablation.

Related Videos
A panel of 6 experts on colorectal cancer
A panel of 6 experts on colorectal cancer
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,